{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:18:50Z","timestamp":1791220730569,"version":"4.1.0"},"reference-count":40,"publisher":"American Diabetes Association","issue":"2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,2,1]]},"abstract":"<jats:p>OBJECTIVE\u2014Sedentary lifestyle and a western diet promote subacute-chronic inflammation, obesity, and subsequently dysglycemia. The aim of the current study was to evaluate the efficacy of the anti-inflammatory drug salsalate to improve glycemia by reducing systemic inflammation in obese adults at risk for the development of type 2 diabetes.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014In a double-masked, placebo controlled trial, we evaluated 20 obese nondiabetic adults at baseline and after 1 month of salsalate or placebo.<\/jats:p>\n               <jats:p>RESULTS\u2014Compared with placebo, salsalate reduced fasting glucose 13% (P &amp;lt; 0.002), glycemic response after an oral glucose challenge 20% (P &amp;lt; 0.004), and glycated albumin 17% (P &amp;lt; 0.0003). Although insulin levels were unchanged, fasting and oral glucose tolerance test C-peptide levels decreased in the salsalate-treated subjects compared with placebo (P &amp;lt; 0.03), consistent with improved insulin sensitivity and a known effect of salicylates to inhibit insulin clearance. Adiponectin increased 57% after salsalate compared with placebo (P &amp;lt; 0.003). Additionally, within the group of salsalate-treated subjects, circulating levels of C-reactive protein were reduced by 34% (P &amp;lt; 0.05).<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014This proof-of-principle study demonstrates that salsalate reduces glycemia and may improve inflammatory cardiovascular risk indexes in overweight individuals. These data support the hypothesis that subacute-chronic inflammation contributes to the pathogenesis of obesity-related dysglycemia and that targeting inflammation may provide a therapeutic route for diabetes prevention.<\/jats:p>","DOI":"10.2337\/dc07-1338","type":"journal-article","created":{"date-parts":[[2008,1,28]],"date-time":"2008-01-28T22:25:09Z","timestamp":1201559109000},"page":"289-294","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":301,"title":["Salsalate Improves Glycemia and Inflammatory Parameters in Obese Young Adults"],"prefix":"10.2337","volume":"31","author":[{"given":"Amy","family":"Fleischman","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Joslin Diabetes Center, Boston, Massachusetts"},{"name":"Children's Hospital Boston, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Shoelson","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Joslin Diabetes Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Bernier","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Joslin Diabetes Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison B.","family":"Goldfine","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Joslin Diabetes Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031216251876400_R1","doi-asserted-by":"crossref","unstructured":"Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med\u2008352: 1685\u20131695, 2005","DOI":"10.1056\/NEJMra043430"},{"key":"2022031216251876400_R2","doi-asserted-by":"crossref","unstructured":"Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest\u2008116: 1793\u20131801, 2006","DOI":"10.1172\/JCI29069"},{"key":"2022031216251876400_R3","unstructured":"Ebstein W: Zur therapie des diabetes mellitus, insbesondere u\u0308ber die anwendeng der salicylauren natron bei demselben. Berl Klin Wochenschr\u200813: 337\u2013340, 1876"},{"key":"2022031216251876400_R4","doi-asserted-by":"crossref","unstructured":"Williamson R: On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J\u20081: 760\u2013762, 1901","DOI":"10.1136\/bmj.1.2100.760"},{"key":"2022031216251876400_R5","doi-asserted-by":"crossref","unstructured":"Reid J, Macdougall AI, Andrews MM: Aspirin and diabetes mellitus. Br Med J\u200833: 1071\u20131074, 1957","DOI":"10.1136\/bmj.2.5053.1071"},{"key":"2022031216251876400_R6","doi-asserted-by":"crossref","unstructured":"Gilgore S: The influence of salicylate on hyperglycemia. Diabetes\u20089: 392\u2013393, 1960","DOI":"10.2337\/diab.9.5.392"},{"key":"2022031216251876400_R7","doi-asserted-by":"crossref","unstructured":"Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest\u2008109: 1321\u20131326, 2002","DOI":"10.1172\/JCI0214955"},{"key":"2022031216251876400_R8","doi-asserted-by":"crossref","unstructured":"Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk\u03b2. Science\u2008293: 1673\u20131677, 2001","DOI":"10.1126\/science.1061620"},{"key":"2022031216251876400_R9","doi-asserted-by":"crossref","unstructured":"Kopp E, Ghosh S: Inhibition of NF-\u03baB by sodium salicylate and aspirin. Science\u2008265: 956\u2013959, 1994","DOI":"10.1126\/science.8052854"},{"key":"2022031216251876400_R10","doi-asserted-by":"crossref","unstructured":"Estes D, Kaplan K: Lack of platelet effect with the aspirin analog, salsalate. Arthritis Rheum\u200823: 1303\u20131307, 1980","DOI":"10.1002\/art.1780231113"},{"key":"2022031216251876400_R11","doi-asserted-by":"crossref","unstructured":"Mielants H, Veys EM, Verbruggen G, Schelstraete: Comparison of serum salicylate levels and gastro-intestinal blood loss between salsalate (Disalcid)and other forms of salicylates. Scand J Rheumatol\u200810: 169\u2013173, 1981","DOI":"10.3109\/03009748109095292"},{"key":"2022031216251876400_R12","doi-asserted-by":"crossref","unstructured":"Diagnosis and classification of diabetes mellitus. Diabetes Care\u200828: S37\u2013S42, 2005","DOI":"10.2337\/diacare.28.suppl_1.S37"},{"key":"2022031216251876400_R13","doi-asserted-by":"crossref","unstructured":"Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care\u200827: 1487\u20131495, 2004","DOI":"10.2337\/diacare.27.6.1487"},{"key":"2022031216251876400_R14","unstructured":"April P, Abeles M, Baraf H, Cohen S, Curran N, Doucette M, Ekholm B, Goldlust B, Knee CM, Lee E, et al.: Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? Semin Arthritis Rheum\u200819: 20\u201328, 1990"},{"key":"2022031216251876400_R15","doi-asserted-by":"crossref","unstructured":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA\u2008285: 2486\u20132497, 2001","DOI":"10.1001\/jama.285.19.2486"},{"key":"2022031216251876400_R16","doi-asserted-by":"crossref","unstructured":"Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984\u20131998. Arch Intern Med\u2008163: 93\u201399, 2003","DOI":"10.1001\/archinte.163.1.93"},{"key":"2022031216251876400_R17","doi-asserted-by":"crossref","unstructured":"Duncan BB, Schmidt MI: The epidemiology of low-grade chronic systemic inflammation and type 2 diabetes. Diabetes Technol Ther\u20088: 7\u201317, 2006","DOI":"10.1089\/dia.2006.8.7"},{"key":"2022031216251876400_R18","doi-asserted-by":"crossref","unstructured":"Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, Kochba I, Rudich A: Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med\u2008353: 1454\u20131462, 2005","DOI":"10.1056\/NEJMoa050080"},{"key":"2022031216251876400_R19","unstructured":"Gilgore SG, Rupp JJ: Response of blood glucose to intravenous salicylate. Metabolism\u200810: 419\u2013421, 1961"},{"key":"2022031216251876400_R20","doi-asserted-by":"crossref","unstructured":"Baron SH: Salicylates as hypoglycemic agents. Diabetes Care\u20085: 64\u201371, 1982","DOI":"10.2337\/diacare.5.1.64"},{"key":"2022031216251876400_R21","doi-asserted-by":"crossref","unstructured":"Loll PJ, Picot D, Garavito RM: The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol\u20082: 637\u2013643, 1995","DOI":"10.1038\/nsb0895-637"},{"key":"2022031216251876400_R22","doi-asserted-by":"crossref","unstructured":"Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I\u03baB kinase-\u03b2. Nature\u2008396: 77\u201380, 1998","DOI":"10.1038\/23948"},{"key":"2022031216251876400_R23","doi-asserted-by":"crossref","unstructured":"Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest\u2008108: 437\u2013446, 2001","DOI":"10.1172\/JCI11559"},{"key":"2022031216251876400_R24","doi-asserted-by":"crossref","unstructured":"Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M: IKK-\u03b2 links inflammation to obesity-induced insulin resistance. Nat Med\u200811: 191\u2013198, 2005","DOI":"10.1038\/nm1185"},{"key":"2022031216251876400_R25","doi-asserted-by":"crossref","unstructured":"Torisu T, Sato N, Yoshiga D, Kobayashi T, Yoshioka T, Mori H, Iida M, Yoshimura A: The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells\u200812: 143\u2013154, 2007","DOI":"10.1111\/j.1365-2443.2007.01044.x"},{"key":"2022031216251876400_R26","doi-asserted-by":"crossref","unstructured":"Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med\u20087: 947\u2013953, 2001","DOI":"10.1038\/90992"},{"key":"2022031216251876400_R27","doi-asserted-by":"crossref","unstructured":"Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med\u20087: 941\u2013946, 2001","DOI":"10.1038\/90984"},{"key":"2022031216251876400_R28","doi-asserted-by":"crossref","unstructured":"You T, Yang R, Lyles MF, Gong D, Nicklas BJ: Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol\u2008288: E741\u2013E747, 2005","DOI":"10.1152\/ajpendo.00419.2004"},{"key":"2022031216251876400_R29","doi-asserted-by":"crossref","unstructured":"Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P: Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes\u200852: 2882\u20132887, 2003","DOI":"10.2337\/diabetes.52.12.2882"},{"key":"2022031216251876400_R30","unstructured":"Roth S, Bennett R, Caldron P, Hartman R, Mitchell C, Doucette M, Ekholm B, Goldlust B, Lee E, Wilson R: Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): an endoscopic study. Semin Arthritis Rheum\u200819: 11\u201319, 1990"},{"key":"2022031216251876400_R31","unstructured":"Disalcid package insert. Northridge, CA, 3M Pharmaceuticals, 1998"},{"key":"2022031216251876400_R32","doi-asserted-by":"crossref","unstructured":"Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med\u2008126: 137\u2013145, 1997","DOI":"10.7326\/0003-4819-126-2-199701150-00008"},{"key":"2022031216251876400_R33","unstructured":"Choi JW: Association between elevated serum hepatic enzyme activity and total body fat in obese humans. Ann Clin Lab Sci\u200833: 257\u2013264, 2003"},{"key":"2022031216251876400_R34","doi-asserted-by":"crossref","unstructured":"Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, Hofmeyer D, Chaudhuri A: Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab\u200889: 5043\u20135047, 2004","DOI":"10.1210\/jc.2004-0436"},{"key":"2022031216251876400_R35","doi-asserted-by":"crossref","unstructured":"Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schonbeck U, Libby P: Metformin inhibits proinflammatory responses and nuclear factor-\u03baB in human vascular wall cells. Arterioscler Thromb Vasc Biol\u200826: 611\u2013617, 2006","DOI":"10.1161\/01.ATV.0000201938.78044.75"},{"key":"2022031216251876400_R36","doi-asserted-by":"crossref","unstructured":"Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab\u200889: 2728\u20132735, 2004","DOI":"10.1210\/jc.2003-032103"},{"key":"2022031216251876400_R37","doi-asserted-by":"crossref","unstructured":"Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P: Nuclear factor-\u03baB suppressive and inhibitor-\u03baB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab\u200886: 3250\u20133256, 2001","DOI":"10.1210\/jc.86.7.3250"},{"key":"2022031216251876400_R38","doi-asserted-by":"crossref","unstructured":"Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H: Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes\u200854: 2404\u20132414, 2005","DOI":"10.2337\/diabetes.54.8.2404"},{"key":"2022031216251876400_R39","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet\u2008368: 1096\u20131105, 2006","DOI":"10.1016\/S0140-6736(06)69420-8"},{"key":"2022031216251876400_R40","doi-asserted-by":"crossref","unstructured":"Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic \u03b2-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes\u200851: 2796\u20132803, 2002","DOI":"10.2337\/diabetes.51.9.2796"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/31\/2\/289\/597951\/zdc00208000289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/31\/2\/289\/597951\/zdc00208000289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T16:53:33Z","timestamp":1647104013000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/31\/2\/289\/25236\/Salsalate-Improves-Glycemia-and-Inflammatory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,1]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc07-1338","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,1]]}}}